NCT01775475View on ClinicalTrials.gov

Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

September 15, 2016

Primary Completion Date

April 1, 2021

Study Completion Date

July 15, 2021

Conditions
AIDS-related Diffuse Large Cell LymphomaAIDS-related Diffuse Mixed Cell LymphomaAIDS-related Diffuse Small Cleaved Cell LymphomaAIDS-related Immunoblastic Large Cell LymphomaAIDS-related Lymphoblastic LymphomaAIDS-related Peripheral/Systemic LymphomaAIDS-related Small Noncleaved Cell LymphomaStage III AIDS-related LymphomaStage IV AIDS-related Lymphoma
Interventions
DRUG

cyclophosphamide

Given IV

DRUG

doxorubicin hydrochloride

Given IV

DRUG

vincristine sulfate

Given IV

DRUG

prednisone

Given PO

DRUG

lomustine

Given PO

DRUG

etoposide

Given PO

DRUG

cyclophosphamide

Given PO

DRUG

procarbazine hydrochloride

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (2)

4606-30100

Moi Teaching and Referral Hospital, Eldoret

Unknown

University of Zimbabwe College of Health Sciences, Harare

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

The Emmes Company, LLC

INDUSTRY

collaborator

University of Arkansas

OTHER

lead

AIDS Malignancy Consortium

NETWORK

NCT01775475 - Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter